A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Summary

The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-295S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor. It will be extended to enroll 10-15 patients at this dose after RP2D is determined, as to further evaluate the safety of RP2D and the preliminary efficacy of HMPL-295S1. In addition, an exploratory study on the pharmacokinetic biomarkers of HMPL-295S1 is planned in this study.

Timeline

Start

2021-05-27

Primary completion

2024-01-29

Completion

2024-02-23

Drugs

Indications